Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II

Timothy M E Davis; Wendy A Davis; Scott D Bringans; James K C Lui; Tasha S C Lumbantobing; Kirsten E Peters; Richard J Lipscombe

doi:10.1186/s40842-024-00191-8

Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II

Timothy M E Davis
, Wendy A Davis
, Scott D Bringans
, James K C Lui
, Tasha S C Lumbantobing
, Kirsten E Peters
, Richard J Lipscombe

Internal Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: There are scant data relating to prognostic biomarkers for chronic kidney disease (CKD) complicating type 1 diabetes. The aim of this study was to assess the performance of the plasma protein biomarker-based PromarkerD test developed and validated for predicting renal decline in type 2 diabetes in the context of type 1 diabetes.

METHODS: The baseline PromarkerD test score was determined in 91 community-based individuals (mean age 46.2 years, 56.5% males) with confirmed type 1 diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II. The performance of the PromarkerD test in predicting the risk of incident CKD (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 in people without CKD at baseline) or an eGFR decline of ≥ 30% over the next four years was determined. The score can range from 0 to 100%, and is categorized as representing low (< 10%), moderate (10% to < 20%) or high (≥ 20%) risk.

RESULTS: The area under the receiver operating characteristic curve was 0.93 (95% confidence interval 0.87-0.99) for the composite renal endpoint, indicating strong predictive accuracy. The positive and negative predictive values at moderate (10% to < 20%) and high (≥ 20%) risk PromarkerD cut-offs were 46.7-50.0% and ≥ 92.0%, respectively.

CONCLUSIONS: These preliminary data suggest that PromarkerD is at least as good a prognostic test for renal decline in type 1 as type 2 diabetes.

Original language	English
Article number	30
Number of pages	5
Journal	Clinical Diabetes and Endocrinology
Volume	10
DOIs	https://doi.org/10.1186/s40842-024-00191-8
Publication status	Published - 10 Oct 2024

Funding

Funders	Funder number
NHMRC National Health and Medical Research Council	513781, 1042231

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40842-024-00191-8Licence: CC BY

The Fremantle Diabetes Study Phase II - A Community Based Study of Diabetes Care Control Complications & Cost
Davis, T. (Investigator 01), Bruce, D. (Investigator 02), Davis, W. (Investigator 03), Chubb, S. (Investigator 04), Starkstein, S. (Investigator 05), Clarke, P. (Investigator 06), McAullay, D. (Investigator 07) & Norman, P. (Investigator 08)
NHMRC National Health and Medical Research Council
1/01/13 → 31/12/18
Project: Research
The Fremantle Diabetes Study Phase II - A Community Based Study of Diabetes Care Control Complications and Cost
Davis, T. (Chief Investigator), Bruce, D. (Chief Investigator), Davis, W. (Chief Investigator), Davis, E. (Chief Investigator), Geelhoed, E. (Chief Investigator) & Knuiman, M. (Chief Investigator)
NHMRC Project Grants
1/01/08 → 31/12/12
Project: Research

Cite this

Davis, T. M. E., Davis, W. A., Bringans, S. D., Lui, J. K. C., Lumbantobing, T. S. C., Peters, K. E., & Lipscombe, R. J. (2024). Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II. Clinical Diabetes and Endocrinology, 10, Article 30. https://doi.org/10.1186/s40842-024-00191-8

@article{8a791bef43804ac7b5c03165e79baf2a,

title = "Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II",

abstract = "BACKGROUND: There are scant data relating to prognostic biomarkers for chronic kidney disease (CKD) complicating type 1 diabetes. The aim of this study was to assess the performance of the plasma protein biomarker-based PromarkerD test developed and validated for predicting renal decline in type 2 diabetes in the context of type 1 diabetes.METHODS: The baseline PromarkerD test score was determined in 91 community-based individuals (mean age 46.2 years, 56.5\% males) with confirmed type 1 diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II. The performance of the PromarkerD test in predicting the risk of incident CKD (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 in people without CKD at baseline) or an eGFR decline of ≥ 30\% over the next four years was determined. The score can range from 0 to 100\%, and is categorized as representing low (< 10\%), moderate (10\% to < 20\%) or high (≥ 20\%) risk.RESULTS: The area under the receiver operating characteristic curve was 0.93 (95\% confidence interval 0.87-0.99) for the composite renal endpoint, indicating strong predictive accuracy. The positive and negative predictive values at moderate (10\% to < 20\%) and high (≥ 20\%) risk PromarkerD cut-offs were 46.7-50.0\% and ≥ 92.0\%, respectively.CONCLUSIONS: These preliminary data suggest that PromarkerD is at least as good a prognostic test for renal decline in type 1 as type 2 diabetes.",

author = "Davis, \{Timothy M E\} and Davis, \{Wendy A\} and Bringans, \{Scott D\} and Lui, \{James K C\} and Lumbantobing, \{Tasha S C\} and Peters, \{Kirsten E\} and Lipscombe, \{Richard J\}",

note = "{\textcopyright} 2024. The Author(s).",

year = "2024",

month = oct,

day = "10",

doi = "10.1186/s40842-024-00191-8",

language = "English",

volume = "10",

journal = "Clinical Diabetes and Endocrinology",

issn = "2055-8260",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes

T2 - the Fremantle Diabetes Study Phase II

AU - Davis, Timothy M E

AU - Davis, Wendy A

AU - Bringans, Scott D

AU - Lui, James K C

AU - Lumbantobing, Tasha S C

AU - Peters, Kirsten E

AU - Lipscombe, Richard J

PY - 2024/10/10

Y1 - 2024/10/10

N2 - BACKGROUND: There are scant data relating to prognostic biomarkers for chronic kidney disease (CKD) complicating type 1 diabetes. The aim of this study was to assess the performance of the plasma protein biomarker-based PromarkerD test developed and validated for predicting renal decline in type 2 diabetes in the context of type 1 diabetes.METHODS: The baseline PromarkerD test score was determined in 91 community-based individuals (mean age 46.2 years, 56.5% males) with confirmed type 1 diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II. The performance of the PromarkerD test in predicting the risk of incident CKD (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 in people without CKD at baseline) or an eGFR decline of ≥ 30% over the next four years was determined. The score can range from 0 to 100%, and is categorized as representing low (< 10%), moderate (10% to < 20%) or high (≥ 20%) risk.RESULTS: The area under the receiver operating characteristic curve was 0.93 (95% confidence interval 0.87-0.99) for the composite renal endpoint, indicating strong predictive accuracy. The positive and negative predictive values at moderate (10% to < 20%) and high (≥ 20%) risk PromarkerD cut-offs were 46.7-50.0% and ≥ 92.0%, respectively.CONCLUSIONS: These preliminary data suggest that PromarkerD is at least as good a prognostic test for renal decline in type 1 as type 2 diabetes.

AB - BACKGROUND: There are scant data relating to prognostic biomarkers for chronic kidney disease (CKD) complicating type 1 diabetes. The aim of this study was to assess the performance of the plasma protein biomarker-based PromarkerD test developed and validated for predicting renal decline in type 2 diabetes in the context of type 1 diabetes.METHODS: The baseline PromarkerD test score was determined in 91 community-based individuals (mean age 46.2 years, 56.5% males) with confirmed type 1 diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II. The performance of the PromarkerD test in predicting the risk of incident CKD (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 in people without CKD at baseline) or an eGFR decline of ≥ 30% over the next four years was determined. The score can range from 0 to 100%, and is categorized as representing low (< 10%), moderate (10% to < 20%) or high (≥ 20%) risk.RESULTS: The area under the receiver operating characteristic curve was 0.93 (95% confidence interval 0.87-0.99) for the composite renal endpoint, indicating strong predictive accuracy. The positive and negative predictive values at moderate (10% to < 20%) and high (≥ 20%) risk PromarkerD cut-offs were 46.7-50.0% and ≥ 92.0%, respectively.CONCLUSIONS: These preliminary data suggest that PromarkerD is at least as good a prognostic test for renal decline in type 1 as type 2 diabetes.

U2 - 10.1186/s40842-024-00191-8

DO - 10.1186/s40842-024-00191-8

M3 - Article

C2 - 39385270

SN - 2055-8260

VL - 10

JO - Clinical Diabetes and Endocrinology

JF - Clinical Diabetes and Endocrinology

M1 - 30

ER -

Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II

Abstract

Funding

UN SDGs

Access to Document

Fingerprint

Projects

The Fremantle Diabetes Study Phase II - A Community Based Study of Diabetes Care Control Complications & Cost

The Fremantle Diabetes Study Phase II - A Community Based Study of Diabetes Care Control Complications and Cost

Cite this